Results 81 to 90 of about 139,987 (302)

Single‐Cell Profiling Identifies SLC2A5‐Mediated Fructose Metabolism as a Vulnerability in Primary CNS Lymphoma

Advanced Science, EarlyView.
Glucose deprivation in the primary CNS lymphoma (PCNSL) tumor microenvironment drives SLC2A5 (encoding GLUT5)‐dependent fructose metabolism in tumor cells, while hypoxia induces HIF‐mediated SLC2A5 expression in tumor‐supportive macrophages, revealing SLC2A5‐driven fructose utilization as a shared and targetable metabolic vulnerability across malignant
Qiaoli Wu, Qianru Zhang, Wenqiang Yan, Lu Sun, Yiran Cui, Bolin Liu, Guoqing Han, Feng Zhang, Ke Pu, Mingchao Zhang, Xiaobing Zhang, Qingguo Li, Gang An, Yuxuan Liu   +13 more
wiley   +1 more source

ESMO Consensus conferences:guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma [PDF]

, 2013
To complement the existing treatment guidelines for all tumour types, ESMO organizes consensus conferences to focus on specific issues in each type of tumour.
Zinzani P, Schmitz N, Pileri, S., Thieblemont, C., Kluin-Nelemans, J. C., Ladetto, M., Gallamini, A., Arcaini L., Hermine, O., PILERI, STEFANO, Zinzani P., Ladetto, Marco, Pileri S., ARCAINI, LUCA, Zucca, E., Wotherspoon A, Kluin-Nelemans J.C., Pileri S, Iannitto E., Le Gouill S, Ladetto M., Thieblemont C, Arcaini L, Le Gouill S., Wotherspoon A., ZINZANI, PIER LUIGI, Ladetto M, Rodriguez J., Rodriguez J, Rodriguez, J., Schmitz, N., Gallamini A, Hermine O., Iannitto, E., Wotherspoon, A., Iannitto E, Zucca E., Kluin Nelemans JC, Hermine O, Gallamini A., Arcaini, L., Thieblemont C., Schmitz N., Dreyling M, Campo E, Campo E., Le Gouill, S., Dreyling, M., Zinzani, P., Campo, E.   +49 more
core   +1 more source

Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy

Annals of Gastroenterological Surgery, EarlyView.
This study evaluated immune‐related biomarkers in esophageal squamous cell carcinoma treated with immune checkpoint inhibitors after postoperative recurrence. PD‐L1 expression in tumor‐associated macrophages and tumor cells, together with HLA class I downregulation and HLA‐DR expression, were associated with favorable responses to immunotherapy.
Kosuke Kanemitsu, Yoshiyuki Tagayasu, Yoshihiro Komohara, Cheng Pan, Rin Yamada, Yukio Fujiwara, Kazuto Harada, Keisuke Kosumi, Yoshifumi Baba, Masaaki Iwatsuki   +9 more
wiley   +1 more source

The function and origin of the CD4+ T cell in the classical Hodgkin lymphoma microenvironment

, 2012
PhDClassical Hodgkin lymphoma (CHL) is a germinal centre B cell malignancy where the bulk of the tumour comprises a non-clonal immune infiltrate enriched for CD4+ T cells.
Greaves, Paul
core  

Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma

, 2011
Background: The prognosis of T-cell lymphoma is poor. To explore the addition of the monoclonal antibody alemtuzumab, we studied the efficacy and tolerability of an intensified alemtuzumab-chemotherapy combination for aggressive T-cell lymphoma in a ...
Luten, M., H.C. Kluin-Nelemans, van Putten, W. L. J., Oudejans, J., W.L.J. van Putten, P.J. Lugtenburg, J. Oudejans, Kooy, M. van Marwijk, van Imhoff, G. W., M. Luten, Kluin-Nelemans, H. C., Lugtenburg, P. J., G.W. van Imhoff, M. van Marwijk Kooy   +13 more
core   +1 more source

Post CAR‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse

American Journal of Hematology, EarlyView.
ABSTRACT CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR‐T surveillance and consolidation strategies.
Snegha Ananth, Neha Agarwal, Bita Sahaf, Allison Jacob, Lik Wee Lee, Heidi Simmons, Ilan Kirsch, Sushma Bharadwaj, Wen‐kai Weng, Melody Smith, Saurabh Dahiya, David Miklos, Matthew J. Frank   +12 more
wiley   +1 more source

Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients

, 2003
In the present study the clinicopathologic and immunophenotypic features of 82 patients with a CD30(-) peripheral T-cell lymphoma, unspecified, presenting in the skin were evaluated.
Meijer, CJLM, Jansen, PM, van Marion, AMW, Vermeer, MH, Bekkenk, MW, Willemze, R, Kluin, PM, Geerts, ML, Cunninga-van Dijk, MR   +8 more
core   +1 more source

Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant

American Journal of Hematology, EarlyView.
ABSTRACT Graft versus host disease (GVHD) prophylaxis with posttransplant cyclophosphamide (ptCY) and cytomegalovirus (CMV) prophylaxis with letermovir have changed the clinical epidemiology of CMV infection. We studied the incidence, risk factors for, and outcomes of CMV infection after Day + 90 of allogeneic hematopoietic cell transplant (alloHCT ...
George L. Chen, Roland Bassett, Rohtesh S. Mehta, Betul Oran, Fareed Khawaja, Ella J. Ariza‐Heredia, Yosra Aljawai, Amanda Olson, May Daher, Portia Smallbone, Katayoun Rezvani, Partow Kebriaei, Uday Popat, Richard Champlin, Roy F. Chemaly, Elizabeth J. Shpall   +15 more
wiley   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

An update on the management of peripheral T-cell lymphoma and emerging treatment options

, 2011
Adrienne A Phillips1, Colette Owens2, Sangmin Lee1, Govind Bhagat31Division of Medical Oncology, Department of Medicine, 2Division of General Medicine, Department of Medicine, 3Department of Pathology and Cell Biology, Columbia University Medical Center ...
Lee S, Bhagat G, Owens C, Phillips AA
core